A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trail of QPI-1007 Delivered by Single or Multi- Dose Intravitreal Injection(s)to Subjects with Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
|Effective start/end date||10/1/15 → 12/31/21|
- QUARK PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.